Akebia Therapeutics, Inc.AKBAEarnings & Financial Report
Akebia Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with kidney diseases, particularly anemia linked to chronic kidney disease. It operates across global markets, focusing on addressing unmet medical needs in the nephrology care segment.
Revenue
$46.5M
Gross Profit
$26.1M
Operating Profit
$-14.3M
Net Profit
N/A
Gross Margin
56.2%
Operating Margin
-30.8%
Net Margin
N/A
YoY Growth
-17.3%
EPS
$-0.10
Akebia Therapeutics, Inc. Q4 FY2024 Financial Summary
Akebia Therapeutics, Inc. reported revenue of $46.5M (down 17.3% YoY) for Q4 FY2024, with a net profit of N/A (N/A margin). Cost of goods sold was $20.4M, operating expenses totaled $40.4M.
Key Financial Metrics
| Total Revenue | $46.5M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 56.2% |
| Operating Margin | -30.8% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
Akebia Therapeutics, Inc. Q4 FY2024 revenue of $46.5M breaks down across 2 segments, led by Products at $44.4M (95.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $44.4M | 95.4% |
| License Collaboration And Other Revenue | $2.1M | 4.6% |
Akebia Therapeutics, Inc. Revenue by Segment — Quarterly Trend
Akebia Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and License Collaboration And Other Revenue) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| License Collaboration And Other Revenue | $3.3M | $2.0M | $2.0M | $1.5M |
Akebia Therapeutics, Inc. Annual Revenue by Year
Akebia Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $236.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $236.2M |
| 2024 | $160.2M |
| 2023 | $194.6M |
| 2022 | $292.5M |
Akebia Therapeutics, Inc. Quarterly Revenue & Net Profit History
Akebia Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $57.6M | +23.9% | N/A | N/A |
| Q3 FY2025 | $58.8M | +57.0% | $540.0K | 0.9% |
| Q2 FY2025 | $62.5M | +43.1% | $247.0K | 0.4% |
| Q1 FY2025 | $57.3M | +75.8% | $6.1M | 10.7% |
| Q4 FY2024 | $46.5M | -17.3% | N/A | N/A |
| Q3 FY2024 | $37.4M | -11.0% | $-20.0M | -53.5% |
| Q2 FY2024 | $43.6M | -22.6% | $-8.6M | -19.7% |
| Q1 FY2024 | $32.6M | -18.5% | $-18.0M | -55.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $32.6M | $43.6M | $37.4M | $46.5M | $57.3M | $62.5M | $58.8M | $57.6M |
| YoY Growth | -18.5% | -22.6% | -11.0% | -17.3% | 75.8% | 43.1% | 57.0% | 23.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $225.5M | $220.2M | $207.1M | $220.7M | $310.2M | $345.6M | $364.2M | $376.6M |
| Liabilities | $252.7M | $253.9M | $257.5M | $269.9M | $285.6M | $316.4M | $322.6M | $344.0M |
| Equity | $-27.3M | $-33.8M | $-50.4M | $-49.2M | $24.6M | $29.2M | $41.6M | $32.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-19.4M | $-10.1M | $-6.7M | $-4.5M | $-13.6M | $22.3M | $28.1M | $31.1M |